EGFR and triple-negative breast carcinoma: In another example, epidermal growth factor receptor (EGFR)-targeted liposomes co-loaded with ginsenoside Rh2 were developed to treat triple-negative breast cancer; an EGFR-binding peptide was anchored on the surface of the liposome, enabling the vesicles to preferentially bind and deliver Rh2 to EGFR-overexpressing tumor cells, resulting in suppressed tumor growth (Gu et al., 2023).